Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.82 PLN | -4.21% | -4.21% | -.--% |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 82.01 | 108.3 | 384.3 | 400.4 | 178.2 | 276.9 |
Enterprise Value (EV) 1 | 148.3 | 169.5 | 428.9 | 444.3 | 235.6 | 322.5 |
P/E ratio | -11.9 x | 32.4 x | 13.4 x | 35.3 x | -68 x | 12.7 x |
Yield | - | - | 1.36% | 0.65% | - | 2.84% |
Capitalization / Revenue | 0.27 x | 0.35 x | 1.05 x | 1.14 x | 0.45 x | 0.62 x |
EV / Revenue | 0.49 x | 0.55 x | 1.18 x | 1.26 x | 0.59 x | 0.73 x |
EV / EBITDA | 14.8 x | 9.42 x | 10.6 x | 18.3 x | 22 x | 7.59 x |
EV / FCF | 8.3 x | 19.6 x | 70.6 x | 106 x | -99.4 x | 29.7 x |
FCF Yield | 12% | 5.11% | 1.42% | 0.94% | -1.01% | 3.36% |
Price to Book | 0.46 x | 0.59 x | 1.81 x | 1.84 x | 0.84 x | 1.18 x |
Nbr of stocks (in thousands) | 86,326 | 87,339 | 87,339 | 87,339 | 87,339 | 87,339 |
Reference price 2 | 0.9500 | 1.240 | 4.400 | 4.585 | 2.040 | 3.170 |
Announcement Date | 4/2/19 | 3/23/20 | 4/12/21 | 4/19/22 | 5/2/23 | 4/25/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 300.8 | 309.9 | 364.8 | 351.9 | 396.6 | 444.5 |
EBITDA 1 | 10 | 17.98 | 40.53 | 24.29 | 10.69 | 42.47 |
EBIT 1 | -0.416 | 8.771 | 31.32 | 15.17 | 1.17 | 32.89 |
Operating Margin | -0.14% | 2.83% | 8.59% | 4.31% | 0.3% | 7.4% |
Earnings before Tax (EBT) 1 | -3.505 | 4.929 | 31.3 | 13.26 | -2.096 | 27.2 |
Net income 1 | -6.58 | 3.345 | 28.63 | 11.6 | -2.266 | 22.22 |
Net margin | -2.19% | 1.08% | 7.85% | 3.3% | -0.57% | 5% |
EPS 2 | -0.0800 | 0.0383 | 0.3278 | 0.1300 | -0.0300 | 0.2500 |
Free Cash Flow 1 | 17.86 | 8.66 | 6.074 | 4.189 | -2.371 | 10.84 |
FCF margin | 5.94% | 2.79% | 1.67% | 1.19% | -0.6% | 2.44% |
FCF Conversion (EBITDA) | 178.56% | 48.17% | 14.99% | 17.25% | - | 25.53% |
FCF Conversion (Net income) | - | 258.91% | 21.22% | 36.12% | - | 48.8% |
Dividend per Share | - | - | 0.0600 | 0.0300 | - | 0.0900 |
Announcement Date | 4/2/19 | 3/23/20 | 4/12/21 | 4/19/22 | 5/2/23 | 4/25/24 |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | 66.3 | 61.2 | 44.6 | 43.9 | 57.5 | 45.6 |
Net Cash position 1 | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | 6.625 x | 3.401 x | 1.1 x | 1.806 x | 5.375 x | 1.074 x |
Free Cash Flow 1 | 17.9 | 8.66 | 6.07 | 4.19 | -2.37 | 10.8 |
ROE (net income / shareholders' equity) | -3.57% | 1.83% | 14.4% | 5.4% | -1.05% | 9.94% |
ROA (Net income/ Total Assets) | -0.08% | 1.67% | 5.85% | 2.68% | 0.2% | 5.43% |
Assets 1 | 8,658 | 200.5 | 488.9 | 433.4 | -1,140 | 409 |
Book Value Per Share 2 | 2.070 | 2.110 | 2.430 | 2.490 | 2.430 | 2.680 |
Cash Flow per Share 2 | 0.0500 | 0.0600 | 0.2100 | 0.1300 | 0.1100 | 0.1600 |
Capex 1 | 8.05 | 3.57 | 8.84 | 17.7 | 6.55 | 9.69 |
Capex / Sales | 2.67% | 1.15% | 2.42% | 5.04% | 1.65% | 2.18% |
Announcement Date | 4/2/19 | 3/23/20 | 4/12/21 | 4/19/22 | 5/2/23 | 4/25/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-6.17% | 250B | |
0.00% | 20.28B | |
+13.52% | 12.04B | |
-19.85% | 8.71B | |
+21.38% | 7.82B | |
+13.29% | 6.19B | |
-7.52% | 3.87B | |
+0.43% | 3.8B | |
-18.30% | 3.73B |
- Stock Market
- Equities
- DMG Stock
- 0QGP Stock
- Financials Dr. Miele Cosmed Group S.A.